Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBPET.L Regulatory News (BPET)

  • There is currently no data for BPET

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Third Quarter Results

24 Nov 2016 07:00

RNS Number : 9912P
F&C Private Equity Trust PLC
24 November 2016
 

To: Stock Exchange

For immediate release:

 

24 November 2016

 

 

F&C Private Equity Trust plc

Quarterly results for the three month period ended 30 September 2016

 

· NAV total return per Ordinary Share of 3.4 per cent for the three month period ended 30 September 2016. 11.9 per cent for the nine month period ended 30 September 2016.

 

· Share price total return per Ordinary Share of 12.5 per cent for the three month period ended 30 September 2016. 14.4 per cent for the nine month period ended 30 September 2016.

 

Manager's Review

 

Introduction

As at the 30 September 2016 the Company's net asset value (NAV) was £240.1 million giving a fully diluted NAV per share of 324.75p, an increase over the quarter of 3.4 per cent. During the period sterling has continued to weaken and this has given rise to a positive currency influence of around 1.8 per cent. A healthy level of activity has been seen with realisations comfortably exceeding drawdowns. As previously announced an interim dividend of 6.12p per share was paid on 4 November 2016.

 

At the end of the period the Company had a cash position of £32.1 million. Together with borrowings of £25.4 million, under the Company's loan facility, net cash was £6.7 million. During the quarter combined realisations and income totalled £19.4 million and drawdowns from funds totalled £4.8 million. There were no new co-investments during the quarter. The total of outstanding undrawn commitments at 30 September was £107.5 million and of this around £17 million is to funds where the investment period has expired.

 

New Investments

The third quarter has been an active one for fresh commitments to private equity funds. The emphasis has been on strengthening some of our longstanding European relationships whilst selectively adding new ones. The European mid-market for buyouts is our focus. New commitments are as follows: £5 million to Piper Private Equity VI, the consumer brands specialists whom we have backed three times before; €9 million to Bencis V, the Benelux focused mid-market fund investing in companies with enterprise values in the range €20-€100 million; €5 million to Montefiore IV, a primarily France-focused fund investing in the €25-€250 million size range, and €6.3 million and €1.2 million respectively to DBAG VII and DBAG VII B which will invest in German speaking European deals in the €75-€250 million size range. After the quarter end we have committed to two Nordic focused funds: €7 million to Procuritas VI and €4 million (40 million SEK) to Summa I. Procuritas is a long standing relationship, but Summa is a new emerging manager bringing together executives from leading Nordic houses.

 

There were no new co-investments in the quarter but after the quarter end we have invested £2.6 million for 12 per cent of Babington, the Derby-based provider of apprenticeships and other business training courses. This deal is led by RJD Partners, with whom we have a longstanding link. The investment thesis is based around the government mandated growth in apprenticeships which is coming through over the next few years, in part funded by the apprenticeship levy.

 

New investments made by the funds have included £0.7 million for Barber of Sheffield, a provider of consumables to the large and growing tattoo parlour sector (RJD Private Equity III), £0.6 million for Questionmark, a provider of human resources and assessment and certification tools (FPE II), £0.3 million for HRA Pharma, a France based speciality pharmaceutical company (Astorg VI), £0.3 million for Palex, a Spanish distributor of healthcare equipment (Corpfin Capital IV) and £0.2 million for Orbis, a company running autism specialist schools in Wales (August Equity Partners III), amongst several others.

 

Realisations

Total realisations for the quarter were £19.4 million, bringing the year to date total to £38.6 million, which is almost 70 per cent of the amount at the same stage last year, an exceptional year for exits. There have been a number of notable successes. As mentioned in the previous report, our investment in the Agilitas-led deal, Ionisos, gave us exposure to a fast growing company involved in the cold sterilisation market in France and neighbouring countries. This uses the radioactive isotope Cobalt 60 to sterilise medical equipment and packaging. After a hold period of only 19 months Agilitas sold the company to leading French private equity house, Ardian, achieving an excellent return of 2.9x and an IRR of 97 per cent. The proceeds were £5.2 million. This is an excellent example of the benefits of investing in unusual niche companies with strongly growing underlying markets into which they can gain market share and where there are significant barriers to entry.

 

Another successful niche company Marston, was sold by Inflexion to ICG achieving an excellent return to us, across two funds, of £5.4 million. Marston is now the UK's leading debt enforcement business, having been repositioned from being a regional collector of limited debt types to the only national collector across multiple liabilities for both government and commercial clients. Chequers Capital has exited TCR, the Belgium based leasing company specialising in ground support equipment for aircraft. This returned £0.9 million representing 8.6x cost and an IRR of 26 per cent. Corpfin Capital IV have sold Spanish logistics company, Logiters, to a trade buyer achieving 11x cost and returning £0.5 million; Herkules Private Equity III sold Norway based Harding, the leading life boat producer to Palfinger. This company has faced challenging conditions given the depressed oil sector, a major market for them, but the proceeds of £0.7 million represented 1.4x cost and an IRR of 13 per cent. Lastly the Environmental Technologies Fund has exited Enbalon, a provider of enterprise stability software, through a sale to Wolters Kluwer achieving 3x cost and an IRR of 23 per cent and proceeds of £0.8 million.

 

Valuation Changes

There have been a number of modest, but cumulatively significant, uplifts over the quarter. DBAG V is up by £0.8 million reflecting good progress across several holdings. Procuritas Capital IV is up by £0.5 million mainly reflecting an uplift for ice cream machine manufacturer Green Magnum. In the co-investment portfolio Park Holidays, our caravan holiday park investment, is trading well and is up by £0.7 million and Avalon, the funeral plans business led by Lonsdale, is also trading well and is up by £0.5 million. On the negative side Hutton Collins Capital Partners III is down by £0.6 million, mainly reflecting a write-down for Byron Burgers which had a well-publicised incident involving the immigration authorities, which has resulted in a damaging, but probably temporary, loss of sales in July and August. The portfolio of Italian funds (PM & Partners II, Progressio II, Mid-Capital Mezzanine and ILP III) was down by £0.5 million reflecting, amongst other factors, a decline in the price of quoted company Italian Wine Brands.

 

Financing

The Company is currently in a net cash position with effectively all of its £70 million borrowing facility available. The portfolio is very broadly based and provides a very suitable asset base against which to borrow. It is the Company's intention to employ a moderate amount of gearing to enhance returns to shareholders over the long term. The recent past has seen a continuation of the strong flow of realisations and this has kept the balance sheet ungeared. A number of investment opportunities are under consideration which could move the balance sheet back into a modestly geared position over the coming months. The Company's level of outstanding commitments has been increased deliberately in order to make sure that the proceeds of realisations are deployed steadily and broadly across our favoured markets.

 

Outlook

The last few months have seen an unusual amount of political change, but limited economic consequences of these changes as yet. The private equity market in Europe continues to pursue and make deals in a largely unaltered way, factoring in, as far as possible, the expected changes arising from Brexit or the handover in the US Presidency. The exits from our portfolio show quite clearly the benefits of investing into the lower mid-market of Europe, namely that there is a very wide range of specialised and basically undiscovered businesses which are able to achieve strong growth through concentrating on their particular niche markets. Our investment partners, who are found in every corner of the Continent and further afield, spend much of their energy in the search for such attractive opportunities, usually building deep local networks with company owners, advisers and investors. They also develop or acquire the specific skills and knowledge to implement value creative change in the companies in which they invest. In every case our investments are arranged such that the interests of our investment partners, those of company management and of our shareholders are directly and closely aligned. The combination of deliberative, informed selection followed by highly-motivated, involved, value-creative change is what distinguishes private equity from other forms of investment management and provides the basis of strong long term returns. From here we expect further growth in shareholder value in the remainder of the year.

 

Hamish Mair

Investment Manager

F&C Investment Business Limited

 

F&C Private Equity Trust plc

 

Statement of Comprehensive Income for the

nine months ended 30 September 2016

 

 

(Unaudited)

 

 

Revenue

£'000

Capital

£'000

Total

£'000

Income

 

 

 

Gains on investments held at fair value

-

33,962

33,962

Exchange losses

-

(3,927)

(3,927)

Investment income

630

-

630

Other income

45

-

45

Total income

675

30,035

30,710

 

 

 

 

Expenditure

 

 

 

Investment management fee - basic fee

(424)

(1,273)

(1,697)

Investment management fee - performance fee

-

(1,508)

(1,508)

Other expenses

(547)

-

(547)

Total expenditure

(971)

(2,781)

(3,752)

 

 

 

 

(Loss)/profit before finance costs and taxation

(296)

27,254

26,958

 

 

 

 

Finance costs

(313)

(940)

(1,253)

 

 

 

 

(Loss)/profit before taxation

(609)

26,314

25,705

 

 

 

 

Taxation

-

-

-

 

 

 

 

(Loss)/profit for period/total comprehensive income

(609)

26,314

25,705

 

 

 

 

Return per Ordinary Share - Basic

(0.84)p

36.04p

35.20p

Return per Ordinary Share - Fully diluted

(0.83)p

35.59p

34.76p

 

 

 

 

 

 

 

F&C Private Equity Trust plc

 

Statement of Comprehensive Income for the

nine months ended 30 September 2015

 

 

 

(Unaudited)

 

 

Revenue

£'000

 

Capital

£'000

 

Total

£'000

Income

 

 

 

Gains on investments held at fair value

-

16,782

16,782

Exchange gains

-

2,011

2,011

Investment income

5,100

-

5,100

Other income

34

-

34

Total income

5,134

18,793

23,927

 

 

 

 

Expenditure

 

 

 

Investment management fee - basic fee

(380)

(1,139)

(1,519)

Investment management fee - performance fee

-

(1,293)

(1,293)

Other expenses

(507)

-

(507)

Total expenditure

(887)

(2,432)

(3,319)

 

 

 

 

Profit before finance costs and taxation

4,247

16,361

20,608

 

 

 

 

Finance costs

(346)

(1,039)

(1,385)

 

 

 

 

Profit before taxation

3,901

15,322

19,223

 

 

 

 

Taxation

(788)

788

-

 

 

 

 

Profit for period/total comprehensive income

3,113

16,110

19,223

 

 

 

 

Return per Ordinary Share - Basic

4.32p

22.31p

26.63p

Return per Ordinary Share - Fully diluted

4.20p

21.72p

25.92p

 

 

 

 

 

 

 

 

 

F&C Private Equity Trust plc

 

Statement of Comprehensive Income for the

year ended 31 December 2015

 

 

(Audited)

 

 

Revenue

£'000

Capital

£'000

Total

£'000

Income

 

 

 

Gains on investments held at fair value

-

17,401

17,401

Exchange gains

-

2,072

2,072

Investment income

7,562

-

7,562

Other income

48

-

48

Total income

7,610

19,473

27,083

 

 

 

 

Expenditure

 

 

 

Investment management fee - basic fee

(509)

(1,528)

(2,037)

Investment management fee - performance fee

-

(1,342)

(1,342)

Other expenses

(696)

-

(696)

Total expenditure

(1,205)

(2,870)

(4,075)

 

 

 

 

Profit before finance costs and taxation

6,405

16,603

23,008

 

 

 

 

Finance costs

(448)

(1,345)

(1,793)

 

 

 

 

Profit before taxation

5,957

15,258

21,215

 

 

 

 

Taxation

(931)

931

-

 

 

 

 

Profit for year/total comprehensive income

5,026

16,189

21,215

 

 

 

 

Return per Ordinary Share - Basic

6.97p

22.44p

29.41p

Return per Ordinary Share - Fully diluted

6.78p

21.85p

28.63p

 

 

 

 

 

 

 

F&C Private Equity Trust plc

 

Amounts Recognised as Dividends

 

 

 

 

 

Nine months ended

30 September 2016 (unaudited)

£'000

Nine months ended

30 September 2015 (unaudited)

£'000

Year

ended

31 December 2015 (audited)

£'000

 

Final Ordinary Share dividend of 5.45p per share for the year ended 31 December 2014

 

-

 

3,939

 

3,939

 

Interim Ordinary Share dividend of 5.58p per share for the year ended 31 December 2015

 

-

 

-

 

4,017

 

Final Ordinary Share dividend of 5.83p per share for the year ended 31 December 2015

 

4,251

 

-

 

-

 

 

 

 

 

4,251

3,939

7,956

 

 

 

F&C Private Equity Trust plc

 

Balance Sheet

 

 

As at 30 September 2016

(unaudited)

As at 30 September 2015(unaudited)As at 31 December 2015

(audited)

 

£'000

£'000

 £'000

Non-current assets

 

 

 

Investments at fair value through profit or loss

235,892

231,243

215,711

 

 

 

 

Current assets

 

 

 

Other receivables

21

26

26

Cash and cash equivalents

32,081

10,890

24,023

 

32,102

10,916

24,049

 

 

 

 

Current liabilities

 

 

 

Other payables

(2,508)

(2,715)

(2,278)

Net current assets

29,594

8,201

21,771

Total assets less current liabilities

265,486

239,444

237,482

 Non-current liabilities

 

 

 

Interest-bearing bank loan

(25,361)

(21,299)

(21,357)

Net assets

240,125

218,145

216,125

 

 

 

 

Equity

 

 

 

Called-up ordinary share capital

739

720

720

Special distributable capital reserve

17,567

15,035

15,040

Special distributable revenue reserve

31,403

31,403

31,403

Capital redemption reserve

1,335

1,335

1,335

Capital reserve

180,065

161,940

158,002

Revenue reserve

9,016

7,712

9,625

Shareholders' funds

240,125

218,145

216,125

 

 

 

 

Net asset value per Ordinary Share - Basic

324.75p

303.05p

300.25p

Net asset value per Ordinary Share - Fully diluted

 

324.75p

 

298.47p

 

295.74p

 

 

F&C Private Equity Trust plc

Reconciliation of Movements in Shareholders' Funds

 

 

 

 

 

Nine months ended 30 September 2016

Nine months ended 30 September 2015

Year

ended 31 December 2015

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

£'000

Opening shareholders' funds

216,125

203,508

203,508

Issue of Ordinary Shares

2,546

-

-

Cancellation of Ordinary Shares

-

(647)

(642)

Profit for the period/total comprehensive income

25,705

19,223

21,215

Dividends paid

(4,251)

(3,939)

(7,956)

Closing shareholders' funds

240,125

218,145

216,125

 

 

Notes (unaudited)

 

1. The unaudited quarterly results have been prepared on the basis of the accounting policies set out in the statutory accounts of the Company for the year ended 31 December 2015. Earnings for the nine months to 30 September 2016 should not be taken as a guide to the results for the year to 31 December 2016.

 

2. Investment management fee:

 

 

 

Nine months ended

30 September 2016

 

 

Nine months ended

30 September 2015

 

 

Year ended

31 December 2015

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Investment management fee - basic fee

424

1,273

1,697

380

1,139

1,519

509

1,528

2,037

Investment management fee - performance fee

-

1,508

1,508

-

1,293

1,293

-

1,342

1,342

 

 

 

 

 

 

 

 

 

 

 

424

2,781

3,205

380

2,432

2,812

509

2,870

3,379

 

 

 

 

 

 

 

 

 

 

 

3. Finance costs:

 

 

 

Nine months ended

30 September 2016

 

 

Nine months ended

30 September 2015

 

 

Year ended

31 December 2015

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Interest payable on bank loan

 

313

 

940

 

1,253

 

346

 

1,039

 

1,385

 

448

 

1,345

 

1,793

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4. The basic return per Ordinary Share is based on a net profit on ordinary activities after taxation of £25,705,000 (30 September 2015 - £19,223,000; 31 December 2015 - £21,215,000) and on 73,017,623 (30 September 2015 - 72,197,658; 31 December 2015 - 72,143,369) shares, being the weighted average number of Ordinary Shares in issue during the period.

 

The fully diluted return per Ordinary Share is based on a net profit on ordinary activities after taxation of £25,705,000 (30 September 2015 - £19,223,000; 31 December 2015 - £21,215,000) and on 73,941,429 (30 September 2015 - 74,156,814; 31 December 2015 - 74,102,525) shares, being the weighted average number of Ordinary Shares in issue during the period after conversion of the Ordinary Share warrants.

 

5. The basic net asset value per Ordinary Share is based on net assets at the period end of £240,125,000 (30 September 2015 - £218,145,000; 31 December 2015 - £216,125,000) and on 73,941,429 (30 September 2015 - 71,982,273; 31 December 2015 - 71,982,273) shares, being the number of Ordinary Shares in issue at the period end.

 

The fully diluted net asset value per Ordinary Share is based on net assets at the period end of £240,125,000 (30 September 2015 - £220,691,000; 31 December 2015 - £218,671,000) and on 73,941,429 (30 September 2015 - 73,941,429; 31 December 2015 - 73,941,429) shares, being the number of Ordinary Shares in issue at the period end after conversion of the Ordinary Share warrants.

 

6. During the period, the Company issued 1,959,156 Ordinary Shares of 1p each in capital of the Company for a consideration of £2,546,000, payable in cash, following the exercise of subscription rights by holders of a corresponding number of management warrants previously issued by the Company in the capital of the Company. The surplus of cash received for the issue of shares over the par value of such shares is £2,527,000 and is credited to the special distributable capital reserve. No warrants remain in issue.

 

7. The financial information for the nine months ended 30 September 2016, which has not been audited or reviewed by the Company's auditor, comprises non-statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2015, on which the auditor issued an unqualified report, have been lodged with the Registrar of Companies. The quarterly report is available on the Company's website www.fcpet.co.uk.

 

 

 

For more information, please contact:

 

F&C Investment Business Limited 0131 718 1000

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTUORBRNUAAUAA
Date   Source Headline
30th Jun 20223:22 pmRNSChange of Name
17th Jun 20224:07 pmRNSTransaction in Own Shares
15th Jun 20225:01 pmRNSTransaction in Own Shares
27th May 20229:08 amRNSResult of Annual Gen Meeting & Directorate Change
26th May 202212:02 pmRNS1st Quarter Results
27th Apr 202210:07 amRNSDirector/PDMR Shareholding
27th Apr 202210:06 amRNSDirector/PDMR Shareholding
27th Apr 202210:04 amRNSDirector/PDMR Shareholding
26th Apr 20223:24 pmRNSDirector/PDMR Shareholding
26th Apr 20223:23 pmRNSDirector/PDMR Shareholding
25th Apr 20229:24 amRNSDirector/PDMR Shareholding
8th Apr 20227:00 amRNSAnnual Financial Report
1st Apr 202210:17 amRNSHolding(s) in Company
1st Apr 202210:09 amRNSHolding(s) in Company
30th Mar 20222:56 pmRNSDirector/PDMR Shareholding
30th Mar 20222:54 pmRNSDirector/PDMR Shareholding
25th Mar 20227:00 amRNSAnnual Financial Report
17th Feb 20227:00 amRNSDirectorate Change
14th Jan 20227:00 amRNSUpdate on Secondary Placing
13th Jan 20227:00 amRNSProposed Secondary Placing
4th Jan 20227:00 amRNSInvestor Presentation
26th Nov 20217:00 amRNS3rd Quarter Results
22nd Nov 202110:47 amRNSHolding(s) in Company
15th Oct 20219:55 amRNSHolding(s) in Company
15th Oct 20217:00 amRNSKepler Trust Intelligence: New Research
27th Aug 20217:00 amRNSInterim results and Quarterly Dividend
25th Jun 20213:14 pmRNSHolding(s) in Company
27th May 20212:15 pmRNSAGM Statement
27th May 202111:51 amRNSQuarterly NAV and Dividend Announcement
29th Apr 20211:01 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSAnnual Financial Report
26th Mar 20217:00 amRNSFinal Results
24th Mar 20217:00 amRNSInvestment Update
8th Feb 20213:00 pmRNSHolding(s) in Company
9th Dec 20209:22 amRNSHolding(s) in Company
27th Nov 202010:52 amRNSHolding(s) in Company
25th Nov 20209:18 amRNSKepler Trust Intelligence: New Research
20th Nov 20207:00 amRNSQuarterly results and dividend announcement
15th Oct 20204:09 pmRNSNon-Executive Director Declaration
18th Sep 20202:09 pmRNSDirector/PDMR Shareholding
16th Sep 20202:24 pmRNSDirector/PDMR Shareholding
15th Sep 20203:42 pmRNSHolding(s) in Company
1st Sep 202012:24 pmRNSDirector/PDMR Shareholding
21st Aug 20207:00 amRNSInterim Results
20th Jul 20207:00 amRNSNon-Executive Director Declaration
17th Jul 20207:00 amRNSAppointment of Corporate Broker
9th Jun 20209:57 amRNSHolding(s) in Company
4th Jun 20207:00 amRNSDirectorate Change
22nd May 20204:11 pmRNSHolding(s) in Company
21st May 20207:00 amRNSFirst Quarter Results and Dividend Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.